Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines

Journal of Chemotherapy

Volumn 22, Issue 2, 2010, Pages 129-133

  Chefrour, M ^a,b   Fischel, J L ^a   Formento, P ^a   Giacometti, S ^b   Ferri Dessens, R M ^c   Marouani, H ^b   Francoual, M ^a   Renee N ^a   Mercier, C ^b   Milano, G ^a   Ciccolini, J ^b  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Roche   (France)

Author keywords

Capecitabine; Erlotinib; Pancreatic cancer; Resistance; VEGF

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN BAX; PROTEIN KINASE B; PROTEIN P27; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

EID: 77951518410     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.2.129     Document Type: Article

References (30)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55(1): 10-33.
2. Arteaga CL The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(18s): 32s-40s.
3. Yamanaka Y, Friess H, Kobrin M S, et al. Overexpression of Her2/neu oncogene in human pancreatic carcinoma. Hum. Pathol., 1993; 24(10): 1127-1134.
4. Benzoni E, Rossit L, Cojutti A, et at. Analysis ot survival after pancreatic resection for oncological pathologies. Chir Ital 2007; 59(1): 17-25
5. Ouchi KF, Yanagisawa M, Sekiguchi F, et at. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 2006: 57(5): 693-702
6. Twelves C, Trigo JM, Jones R, et al. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study. Eur J Cancer 2008; 44(3): 19-116
7. Van Cutsem E, Verslype C, Beale P, et al. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol 2008; 19(2): 332-339 (Pubitemid 351201716)
8. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refrectory advanced pancreatic cancer. J Clin Oncol 2007; 25(30): 4787-4792 (Pubitemid 350086482)
9. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004; 22(13): 2610-2616. (Pubitemid 41103748)
10. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase Ill trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B J Clin Oncol, ASCO Annual Meeting Proceedings Part 1 2007; 25: 4508.
11. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol ASCO Annual Meeting Proceedings Part I 2007; 25: LBA4509.
12. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007: 25(15): 1960-1966. (Pubitemid 46972777)
13. Von Marschall Z, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroentorology 2000; 119(5): 1358-1372.
14. Carmichael J, DeGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47(4): 936-942. (Pubitemid 17027905)
15. Chou TC. Talalay P. Quantitative analysis of dose-effect relationships: the combined eftects of multiple drugs or enzyme inihibitors. Adv Enzyme Regul 1984; 22: 27-55.
16. Bozec A, Lassalle S, Gugenheim J, et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006; 95(6): 722-728. (Pubitemid 44373488)
17. Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990: 50(1): 197 201. (Pubitemid 20030018)
18. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10(7): 1171-1175.
19. Evrard A, Cuq P, Ciccolini J. et al. Increased cytotoxicity and by-stander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 1999; 80(11): 1726-1733 (Pubitemid 29389624)
20. Olivier S, Formento P. Fischel JL, et al. Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J Cancer 1990; 26(8): 867-871.
21. Formento JL, Francoual M, Formento P, et al. Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer. Breast Cancer Res Treat 1991; 17(3): 211-219.
22. Kieser A, Weich HA Brandner G, et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9(3): 963-969. (Pubitemid 24065938)
23. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver end cancer tissue. Eur J Cancer 1998; 34(8): 1274-1281 (Pubitemid 28342121)
24. Nishimura G, Terada I, Kobayashi T, et al. Thymidine phosphorylase and dihydroprimnidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5-deoxy-5-fluoroumidine as adjuvant chemotherapy. Oncol Rep 2002; 9(3): 479.
25. Jonckheere N, Perrais M, Mariette C, et al. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene. 2004; 23(34): 5729-5738 (Pubitemid 39093018)
26. Shirk AJ, Kuver R. Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. BMC Gastroenterol. 2005, 31. 5-12 (Pubitemid 41363864)
27. Matet- Martino MC, Faure F, Vialaneix JP, et al. Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinomCancer Chemother Pharmacol. 1986;18(1): 5-10.
28. Mohiuddin M, Chendil D, Dey S, et al. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells. Anticancer Res. 2002: 22(2A): 825-830 (Pubitemid 34475236)
29. Kalthoff H, Schmiegel W, Roeder C, et al. p53 and K-RAS alterations in pancreatic epithetial cell lesions. Oncogene 1993; 8(2): 289-298 (Pubitemid 23073744)
30. Ko AH, Dito E, Schillinger B, et al. . A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC). J Clin Oncol 2008: 26(5): 4516.